Matos E - Search Results

1

Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: a case report.

Kuhar CG, Matos E. Kuhar CG, et al. Among authors: matos e. BMC Res Notes. 2014 May 31;7:325. doi: 10.1186/1756-0500-7-325. BMC Res Notes. 2014. PMID: 24884941 Free PMC article.

2

Effectiveness of adjuvant trastuzumab in daily clinical practice.

Matos E, Zakotnik B, Kuhar CG. Matos E, et al. Radiol Oncol. 2014 Nov 5;48(4):403-7. doi: 10.2478/raon-2013-0081. eCollection 2014 Dec. Radiol Oncol. 2014. PMID: 25435855 Free PMC article.

3

Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.

Ovcaricek T, Takac I, Matos E. Ovcaricek T, et al. Among authors: matos e. Radiol Oncol. 2019 Sep 24;53(3):285-292. doi: 10.2478/raon-2019-0038. Radiol Oncol. 2019. PMID: 31553709 Free PMC article. Review.

4

Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer - results from a real-world setting.

KovaČ A, Matos E, Kuhar CG, Čakš M, Ovčariček T, Mencinger M, Humar M, Borštnar S. KovaČ A, et al. Among authors: matos e. Cancer Treat Res Commun. 2020;25:100201. doi: 10.1016/j.ctarc.2020.100201. Epub 2020 Aug 27. Cancer Treat Res Commun. 2020. PMID: 32979704 Free article.

5

Breast cancer during pregnancy: retrospective institutional case series.

Matos E, Ovcaricek T. Matos E, et al. Radiol Oncol. 2021 May 4;55(3):362-368. doi: 10.2478/raon-2021-0022. Radiol Oncol. 2021. PMID: 33939895 Free PMC article.

6

Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer.

Kuhar CG, Borštnar S, Gazić B, Matos E. Kuhar CG, et al. Among authors: matos e. Breast. 2023 Jun;69:481-490. doi: 10.1016/j.breast.2023.01.011. Epub 2023 Jan 24. Breast. 2023. PMID: 36740512 Free PMC article.

7

Triple negative breast cancer - prognostic factors and survival.

Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Ovcaricek T, et al. Among authors: matos e. Radiol Oncol. 2011 Mar;45(1):46-52. doi: 10.2478/v10019-010-0054-4. Epub 2010 Dec 31. Radiol Oncol. 2011. PMID: 22933934 Free PMC article.

8

A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.

Matos E, Jug B, Blagus R, Zakotnik B. Matos E, et al. Arq Bras Cardiol. 2016 Jul;107(1):40-7. doi: 10.5935/abc.20160084. Epub 2016 Jun 10. Arq Bras Cardiol. 2016. PMID: 27305108 Free PMC article.

9

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. Cardoso F, et al. Among authors: matos e. N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253. N Engl J Med. 2016. PMID: 27557300 Free article. Clinical Trial.

10

Intraoperative Touch Imprint Cytology in Breast Cancer Patients After Neoadjuvant Chemotherapy.

Hadalin V, Pislar N, Borstnar S, Matos E, Kovac A, Dobovisek L, Cankar K, Perhavec A. Hadalin V, et al. Among authors: matos e. Clin Breast Cancer. 2022 Jun;22(4):e597-e603. doi: 10.1016/j.clbc.2021.12.013. Epub 2022 Jan 5. Clin Breast Cancer. 2022. PMID: 35086763

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

397 results

Search Page

Filters